Therapeutics News and Research

RSS

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

1 Feb 2011

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

1 Feb 2011

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Avantra Biosciences today announced the selection of TGen Drug Development as a key test site for Avantra's new biomarker quantitation platform.

1 Feb 2011

FDA schedules panel meeting date for BioMimetic Therapeutics's Augment Bone Graft PMA

BioMimetic Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled an Orthopedic and Rehabilitation Devices Panel meeting on May 12, 2011 to review the Company's Premarket Approval (PMA) application for Augment™ Bone Graft for the treatment of foot and ankle fusions in the U.S.

1 Feb 2011

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

1 Feb 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Alexion announces acquisition of Taligen Therapeutics

Alexion Pharmaceuticals, announced that it has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, Mass.

31 Jan 2011

EU grants 3.3 million to AMP for gene therapy development against AIP

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Union has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria.

31 Jan 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

PPTA offers new DVD on plasma donation

Anyone curious about what to expect as a plasma donor and how plasma contributes to lifesaving medicines can now learn about the process thanks to a new DVD from the Plasma Protein Therapeutics Association.

29 Jan 2011

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

Pain Therapeutics, today announced that it had received a $5,000,000 milestone payment from King Pharmaceuticals, its exclusive commercial partner for abuse-resistant prescription pain medications.

29 Jan 2011

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

Misaligned research, medical challenges and harsh economics are thwarting efforts to slow the destructive course of Alzheimer's disease in the United States, according to a trio of nationally regarded Alzheimer's researchers writing a "Perspective" in Jan. 27 issue of the journal Neuron.

28 Jan 2011

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

28 Jan 2011

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome caused by shiga toxin II secreting E.coli O157: H7 strain.

28 Jan 2011

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.

28 Jan 2011

Therapeutics News and Research

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

OPKO Health acquires CURNA

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

FDA schedules panel meeting date for BioMimetic Therapeutics's Augment Bone Graft PMA

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Alexion announces acquisition of Taligen Therapeutics

EU grants 3.3 million to AMP for gene therapy development against AIP

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

PPTA offers new DVD on plasma donation

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News